Guidelines

ADVI’s Lindsay Bealor Greenleaf takes a look at the regulatory efforts that marked 2018 — and forecasts what 2019 may hold.

The FDA has approved Glenmark's generics DermOtic Oil and Westcort ointment, which had a market value of about $18.1 million, and $11.1 million respectively.

Pharmacists took third place in Gallup's 2018 survey of honesty, with doctors ranking second, and nurses placing first.

Mylan has received the FDA's OK for generic Canasa, which had a market value of roughly $263 million.

Novadoz has received FDA clearance for generic Rapaflo, which is indicated for the symptomatic relief in men experiencing the condition benign prostatic hyperplasia.

Lynparza is the first PARP inhibitor approved for first-line maintenance in BRCAm advanced ovarian cancer.

Ananda Professional announced its sponsorship of a study that showcases how hemp-derived CBD can affect a patient’s willingness to taper their opioid usage in a positive way.

Vitruvius recently received the FDA's approval for generic Amicar, which has a market value of roughly $26.2 million.